Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Shimazu Y, Kanda J, Onda Y, Fuchida SI, Ohta K, Shimura Y, Kosugi S, Yamamura R, Matsuda M, Hanamoto H, Adachi Y, Anzai N, Hotta M, Fukushima K, Yagi H, Yoshihara S, Tanaka Y, Takakuwa T, Tanaka H, Shibayama H, Uoshima N, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. Shimazu Y, et al. Among authors: kuroda j. Cancer Immunol Immunother. 2024 May 17;73(7):135. doi: 10.1007/s00262-024-03711-8. Cancer Immunol Immunother. 2024. PMID: 38758239 Free PMC article.
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first-line treatment: A 15-year follow-up of patients with advanced follicular lymphoma in JCOG0203.
Watanabe T, Matsuno Y, Wakabayashi M, Maruyama D, Yamamoto K, Kubota N, Shimada K, Asagoe K, Yamaguchi M, Ando K, Ogura M, Kuroda J, Suehiro Y, Tsukasaki K, Tobinai K, Nagai H. Watanabe T, et al. Among authors: kuroda j. Hematol Oncol. 2024 May;42(3):e3272. doi: 10.1002/hon.3272. Hematol Oncol. 2024. PMID: 38595316 Clinical Trial.
Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021).
Shibayama H, Itagaki M, Handa H, Yokoyama A, Saito A, Kosugi S, Ota S, Yoshimitsu M, Tanaka Y, Kurahashi S, Fuchida SI, Iino M, Shimizu T, Moriuchi Y, Toyama K, Mitani K, Tsukune Y, Kada A, Tamura H, Abe M, Iwasaki H, Kuroda J, Takamatsu H, Sunami K, Kizaki M, Ishida T, Saito T, Matsumura I, Akashi K, Iida S. Shibayama H, et al. Among authors: kuroda j. Int J Hematol. 2024 Mar 29. doi: 10.1007/s12185-024-03754-8. Online ahead of print. Int J Hematol. 2024. PMID: 38548963
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, Yamauchi T, Kiyoi H, Yokota A, Ikezoe T, Katsuoka Y, Takada S, Aotsuka N, Morita Y, Ishikawa T, Asada N, Ota S, Dohi A, Morimoto K, Imai S, Kishimoto U, Akashi K, Miyazaki Y; Study Group for NS-87/CPX-351. Usuki K, et al. Int J Hematol. 2024 Mar 26. doi: 10.1007/s12185-024-03733-z. Online ahead of print. Int J Hematol. 2024. PMID: 38532078
In vivo imaging of bone collagen dynamics in zebrafish.
Hino H, Kondo S, Kuroda J. Hino H, et al. Among authors: kuroda j. Bone Rep. 2024 Mar 4;20:101748. doi: 10.1016/j.bonr.2024.101748. eCollection 2024 Mar. Bone Rep. 2024. PMID: 38525199 Free PMC article.
Autologous HSCT with novel agent-based induction and consolidation followed by lenalidomide maintenance for untreated multiple myeloma.
Mori Y, Takizawa J, Katsuoka Y, Takezako N, Nagafuji K, Handa H, Kuroda J, Sunami K, Kamimura T, Ogawa R, Kikushige Y, Harada M, Akashi K, Miyamoto T; Japan Study Group for Cell Therapy and Transplantation. Mori Y, et al. Among authors: kuroda j. Cancer Sci. 2024 Mar 18. doi: 10.1111/cas.16158. Online ahead of print. Cancer Sci. 2024. PMID: 38498976 Free article.
Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio.
Ide D, Fujino T, Kobayashi T, Egashira A, Miyashita A, Mizuhara K, Isa R, Tsukamoto T, Mizutani S, Uchiyama H, Kaneko H, Uoshima N, Kawata E, Taniwaki M, Shimura Y, Kuroda J. Ide D, et al. Among authors: kuroda j. Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03750-y. Online ahead of print. Int J Hematol. 2024. PMID: 38492199
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
Nakamura N, Arima N, Takakuwa T, Yoshioka S, Imada K, Fukushima K, Hotta M, Fuchida SI, Kanda J, Uoshima N, Shimura Y, Tanaka H, Ohta K, Kosugi S, Yagi H, Yoshihara S, Yamamura R, Adachi Y, Hanamoto H, Shibayama H, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M; Kansai Myeloma Forum. Nakamura N, et al. Among authors: kuroda j. Ann Hematol. 2024 Mar 16. doi: 10.1007/s00277-024-05705-z. Online ahead of print. Ann Hematol. 2024. PMID: 38492020
FLAIR hyperintense cortical lesions in anti-myelin oligodendrocyte glycoprotein antibody-associated encephalitis with seizure following SARS-CoV-2 mRNA vaccination.
Yoshino F, Ozaki Y, Shibahara T, Matsuoka M, Tachibana M, Ago T, Kitazono T, Kuroda J, Nakane H. Yoshino F, et al. Among authors: kuroda j. eNeurologicalSci. 2023 Dec 22;34:100492. doi: 10.1016/j.ensci.2023.100492. eCollection 2024 Mar. eNeurologicalSci. 2023. PMID: 38469372 Free PMC article. No abstract available.
554 results